BBIOBBIOBBIOCompany Profile
BBIO
BBIOCIK 0001743881 · Quarterly mode · latest period FY2026 (Q2) (ending 2026-06-30) · sourced from SEC EDGAR
At a glance · FY2026 (Q2)
Revenue
$243.68M
+$133.11M +120.4%vs FY2025 (Q2)
Gross Profit
$228.63M
+$121.72M +113.8%vs FY2025 (Q2)
Capital allocation · trailing 4 quarters
how the company spent its cashCapex (TTM)
$1.02M
+$237K+30.46%(2Q26 vs 2Q25)
Dividends paid (TTM)
—
cash returned to holders
Stock buybacks (TTM)
$210M
+$161.73M+335%(2Q26 vs 2Q25)
Balance sheet · 2026-06-30
latest filed snapshotTotal assets
$1.22B
+$137.11M+12.69%(2Q26 vs 2Q25)
Total liabilities
$3.72B
Recent performance · 8 quarters
Revenue+$133.11M +120.4%
Net Income+$27.87M +15.2%
Free Cash Flow+$9.73M +12.0%
Operating Margin+77.5pts
Drill down
BBIO Sankey
See BBIO's revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.
Open SankeyBBIO Charts
8 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.
Open Charts